ISRCTN11652842已完成1 期
Comparative bioavailability study of a new Lorazepam IBSA 2.5 mg orodispersible film vs. Tavor® 2.5 mg tablets and Tavor® 2.5 mg orodispersible tablets in healthy volunteers under fasting conditions
IBSA Institut Biochimique (Switzerland)0 个研究点目标入组 18 人开始时间: 2023年1月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Informed consent: signed written informed consent before inclusion in the study
- •2. Sex and Age: men and women, 18-55 years old inclusive
- •3. Body Mass Index: 18.5-30 kg/m² inclusive
- •4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
- •5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study
- •6. Contraception and fertility (women only): women of child-bearing potential must be using at least one of the following reliable methods of contraception:
- •a. A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
- •b. A male sexual partner who agrees to use a male condom with spermicide
- •c. A sterile sexual partner
- •Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all women, pregnancy test result must be negative at screening and Day -1.
排除标准
- •Subjects meeting any of these criteria will not be enrolled in the study:
- •1. Electrocardiogram (12-lead ECG in supine position): clinically significant abnormalities
- •2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study; presence of mouth lesions or any other oral mucosa alteration; presence or history (within 28 days) of any tongue piercings; presence of any partials, braces or dentures
- •3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
- •4. Allergy: ascertained or presumptive hypersensitivity to the active principle or formulations' ingredients or both; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
- •5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, immunological or neurological diseases that may interfere with the aim of the study
- •6. Medications: medications, including over the counter medications and herbal remedies for 2 weeks before the start of the study. Hormonal contraceptives for women will not be allowed
- •7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
- •8. Blood donation: blood donations for 3 months before this study
- •9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for women and >2 drinks/day for men, defined according to the USDA Dietary Guidelines 2020-2025], caffeine (>5 cups coffee/tea/day) or tobacco abuse (10 cigarettes/day)
- •10. Drug test: positive result at the drug test at screening
- •11. Alcohol test: positive alcohol breath test at Day -1
- •12. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians
- •13. Pregnancy (women only): positive or missing pregnancy test at screening or Day -1, pregnant or lactating women.
研究者
相似试验
进行中（未招募）
不适用
Investigation of the effectiveness of oral lorazepam in managing preoperative dental anxiety in phobic dental patients-A pilot study - Oral lorazepam for managing dental anxiety.Pre operative dental anxiety, in phobic dental patients.EUCTR2005-003749-15-GBMerck, Sharp & Dohme-Clinical Pharmacology,Europe36
已完成
不适用
Relative bioavailability comparison of Alprazolam 0.5mg tablet formulationsIRCT20201212049683N1Raha Pharmaceutical Company24
已完成
1 期
Pharmacokinetic Comparisons of Two Donepezil FormulationsAlzheimer DiseaseNCT01297036Korea University Anam Hospital22
已完成
不适用
Pharmacokinetics and Bioavailability of a New Oral Analgesic: Fentanyl Wafer ('Waferyl' (TM)), in Healthy Volunteers.Pain ManagementAnaesthesiology - Pain managementACTRN12611000106932iX Biopharma Pte Ltd24
尚未招募
1 期
A clinical trial to compare and evaluate the bioavailability of ALDP 001 drug and LASTACAFT drug in healthy adult human subjects under fasting condition.CTRI/2022/07/043825Alkem Laboratories Limited